Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$3.8M Buy
133,388
+6,276
+5% +$167K 0.15% 141
2026
Q2
$3.06M Buy
127,112
+2,467
+2% +$64.5K 0.12% 172
2026
Q1
$3.5M Buy
124,645
+1,766
+1% +$47K 0.16% 134
2025
Q4
$3.06M Buy
122,879
+69,065
+128% +$1.74M 0.14% 150
2025
Q3
$1.37M Sell
53,814
-1,113
-2% -$27.5K 0.1% 185
2025
Q2
$1.33M Sell
54,927
-4,404
-7% -$103K 0.1% 180
2025
Q1
$1.5M Buy
59,331
+26
+0% +$680 0.13% 154
2024
Q4
$1.57M Buy
59,305
+3,507
+6% +$95.1K 0.13% 142
2024
Q3
$1.61M Buy
+55,798
New +$1.63M 0.14% 140

Other funds holding PFE

BFC Planning's PFE Position: Q3 2026 in Review

BFC Planning increased its Pfizer (PFE) stake by 4.9% in Q3 2026, buying an estimated $167K and bringing the position to 133,388 shares worth $3.8M. The position accounts for 0.15% of the portfolio, ranked #141.

BFC Planning first reported a position in PFE in Q3 2024 and has held it in 9 quarters since. 2,556 funds tracked by Wall St. Rank hold PFE as of Q3 2026.

  • BFC Planning held 133,388 shares of Pfizer worth $3.8M as of Q3 2026.
  • BFC Planning bought 6,276 Pfizer shares in Q3 2026, an estimated $167K.
  • Pfizer made up 0.15% of BFC Planning's portfolio in Q3 2026, its #141 holding.
  • BFC Planning first reported a position in Pfizer in Q3 2024 and has held it in 9 quarters since.
  • 2,556 funds tracked by Wall St. Rank held Pfizer as of Q3 2026.

Based on BFC Planning's 13F filing for Q3 2026, filed 13 Nov 2026.